Navigation Links
Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
Date:6/29/2010

QUEBEC CITY, June 29 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that abstract O-0017, entitled, "Subset Analysis of 5-FU Refractory Patients from a Randomized Phase 2 Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC", has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain, from June 30-July 2, 2010. The oral presentation will be made by Paulo Hoff, M.D., Professor of Medicine and Chairman of Medical Oncology at the University of Sao Paulo, Brazil and former lead investigator for the capecitabine (Xeloda(R)) Phase 3 approval study in metastatic colorectal cancer.

Of the 38 patients enrolled in the Phase 2 study, 27 patients were previously refractory to a 5-FU based regimen. A Phase 3 randomized double-blind trial comparing perifosine + capecitabine vs. placebo + capecitabine in 5-FU refractory patients with advanced refractory colorectal cancer (X-PECT trial), under Special Protocol Assessment (SPA) from the Food and Drug Administration (FDA), is currently open and enrolling patients at multiple centers throughout the U.S. This Phase 3 trial is sponsored by Keryx Biopharmaceuticals, Inc. ("Keryx") (Nasdaq: KERX), Aeterna Zentaris' licensee for perifosine in the United States, Canada and Mexico.

About Perifosine

Perifosine, a novel, potentially first-in-class, oral Akt inhib
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
2. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
3. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
4. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
5. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
6. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
7. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
10. AEterna Zentaris Announces Appointment of New Board Member
11. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... Texas (PRWEB) September 20, 2014 ... integrated urological and interventional radiology products and services, ... Inc. subsidiary with Clinicon Corporation for ... expands HealthTronics’ portfolio of minimally invasive, mobile, surgical ... patients. , Under the agreement, HealthTronics will make ...
(Date:9/19/2014)... crop yields to disease risks, the biological characteristics people ... Just as for heightthe textbook example of a complex ... shaped by multiple genetic and environmental influences, making it ... such genes, geneticists typically mate two individuals that differ ... small mouseand then study their descendents, looking for genes ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... and its potential to revolutionize the world has ... multinational corporations and small start-ups. The early years ... research projects largely due to the high risks ... Government budgets earmarked for this evolving technology have ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... Administration (FDA) review, the Company is initiating ... administration of REOLYSIN(R) in,combination with paclitaxel and ... cancers. The Principal Investigator is Dr. Monica ...
... but powerful engine that propels the bacterium Bacillus ... flagellum by a protein clutch, Indiana University Bloomington and ... this week,s Science . , Scientists have ... what causes the flagellum to stop spinning -- temporarily ...
... As President Of ... AeroLEF Division -, ... , TSX: YM, AIM: YMBA), an oncology company that identifies,develops and ... imposed by the US Food and Drug,Administration (FDA) on the development ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3Microscopic 'clutch' puts flagellum in neutral 2Microscopic 'clutch' puts flagellum in neutral 3YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL 2YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL 3
(Date:9/19/2014)... regulate their symbiotic relationship with soil bacteria by ... plant structure from leaves into the roots to ... roots. This collaborative study was conducted by researchers ... Graduate University for Advanced Studies (SOKENDAI), and the ... , Legumes, an important plant family which ...
(Date:9/18/2014)... Miranda, a small, icy moon of Uranus, is one ... the solar system. Despite its relatively small size, Miranda ... that resulted in the formation of at least three ... coronae. , These coronae are visible in Miranda,s ... km across. Arden corona, the largest, has ridges and ...
(Date:9/18/2014)... "frequent flyers" program, fruit flies surely would be eligible ... increasing numbers of fruit fly research studies. One fruit ... and another is scheduled launch to the station Sept. ... December. , Fruit flies are biomedical research models studied ... organisms can reveal the basis for health and disease ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... of the tyrannosaurid, says a University of Alberta researcher ... turn the animal into a "zoological superweapon." , ... tyrannosaurids," said Dr. Eric Snively, a post doctoral research ... instance, was keeping the T. rexes from breaking their ...
... is virus as for example HIV and bird flu able ... the purpose of the virus? Researchers at the University of ... is a collaboration between molecular biologists and physicists. ”The molecular ... the interplay between the intercellular parts, while the physicists have ...
... get older. As sleep quality and quantity typically decrease ... a healthy older man gets can affect his level of ... the April 1st issue of the journal SLEEP. , The ... of Chicago, focused on 12 healthy men between the ages ...
Cached Biology News:Fused nasal bones helped tyrannosaurids dismember prey 2Danish researches solve virus puzzle 2